Screener
Charles River Laboratories CRL Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | June 27, 2026 | December 27, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $140,983 | $148,800 |
| Accrued compensation | 187,835 | 268,854 |
| Deferred revenue | 203,035 | 210,418 |
| Accrued liabilities | 380,101 | 270,085 |
| Other current liabilities | 222,792 | 222,158 |
| Total current liabilities | 1,134,746 | 1,120,315 |
| Long-term debt, net and finance leases | 2,619,985 | 2,136,360 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's deferred revenue?
- Charles River Laboratories (CRL) reported deferred revenue of $203.04M in Q2 2026.
- How has Charles River Laboratories's deferred revenue changed year-over-year?
- Charles River Laboratories's deferred revenue decreased by 24.3% year-over-year, from $268.34M to $203.04M.
- What is the long-term trend for Charles River Laboratories's deferred revenue?
- Over 5 years (2020 to 2025), Charles River Laboratories's deferred revenue has grown at a 0.2% compound annual growth rate (CAGR), from $207.94M to $210.42M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Charles River Laboratories's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude